Clinical trial
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan…
NCT00403052 · Dynavax Technologies Corporation, Industry · Terminated
Key facts
| NCT number | NCT00403052 |
|---|---|
| Title | A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer |
| Official title | Phase 1 Study of the Combination of 1018 ISS, Irinotecan and Cetuximab in Patients With Metastatic Colorectal Cancer Previously Treated With a Fluoropyrimidine, Oxaliplatin or Irinotecan With or Without Bevacizumab |
| Lead sponsor | Dynavax Technologies Corporation, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | 1018 ISS immunostimulatory oligonucleotide |
| Enrollment | 14 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Nov 23, 2006 |
| Last update posted | Apr 16, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: